Octreotide and lanreotide vs Dopamine agonists
How to tell Octreotide and lanreotide and Dopamine agonists apart when a board question makes them look alike.
Somatostatin analogs (octreotide): suppress GH and GI hormones; dopamine agonists (cabergoline, bromocriptine): suppress prolactin.
Side by side
Somatostatin analogs used for acromegaly and secretory neuroendocrine syndromes; gallstones and glucose changes are key adverse effects.
Bromocriptine/cabergoline D2 agonism suppresses prolactin rather than broadly suppressing GH/GI peptide release.
Octreotide and lanreotide activate somatostatin receptors, suppressing GH, insulin, glucagon, and GI peptide release.
Dopamine agonists activate D2 receptors on pituitary lactotrophs to suppress prolactin.
Acromegaly after surgery, carcinoid flushing/diarrhea, VIPoma diarrhea, gallstones, or glucose swings point somatostatin analog.
Galactorrhea, amenorrhea, prolactinoma shrinkage, or prolactin reduction points dopamine agonist.
The trap
Both can touch pituitary endocrinology, but the hormone being suppressed is different.
The repair move
For pituitary peptide drugs, name the target hormone first: (1) acromegaly (excess GH from somatotroph adenoma, IGF-1 elevated, abnormal oral glucose suppression test) needs surgery first; if persistent or unresectable, give somatostatin analog (octreotide LAR or lanreotide); pegvisomant (GH receptor antagonist) is a second-line option; cabergoline is third-line for mild acromegaly; (2) prolactinoma (high prolactin from lactotroph adenoma, galactorrhea and amenorrhea or low testosterone) gets dopamine agonist FIRST regardless of tumor size because dopamine agonists shrink prolactinomas dramatically; surgery is reserved for visual field defects unresponsive to medical therapy.
Try a free question
CoreA patient with acromegaly after incomplete pituitary surgery receives a somatostatin analog that suppresses growth hormone release. Gallstones and glucose changes are reviewed. Which class best fits?
Show answer and explanation
Answer: A. Octreotide or lanreotide. Octreotide and lanreotide are somatostatin analogs used for acromegaly; gallbladder disease and glucose effects are key toxicities.
Why the other choices are tempting
- B. Bromocriptine/cabergoline are dopamine agonists for prolactin suppression.
- C. Levothyroxine/liothyronine are thyroid hormone replacements.
- D. Tamoxifen/raloxifene are SERMs.
- E. Naloxone/naltrexone are opioid antagonists.
Flashcards
Tap a card to flip it.
What is the fastest separator for Octreotide and lanreotide vs Dopamine agonists?
Somatostatin analogs (octreotide): suppress GH and GI hormones; dopamine agonists (cabergoline, bromocriptine): suppress prolactin.
What clue should make you choose Octreotide and lanreotide?
Somatostatin analogs used for acromegaly and secretory neuroendocrine syndromes; gallstones and glucose changes are key adverse effects.
Quick answers
What is the fastest way to tell Octreotide and lanreotide from Dopamine agonists?
Somatostatin analogs (octreotide): suppress GH and GI hormones; dopamine agonists (cabergoline, bromocriptine): suppress prolactin.
What is the key clue for Octreotide and lanreotide?
Somatostatin analogs used for acromegaly and secretory neuroendocrine syndromes; gallstones and glucose changes are key adverse effects.
What is the key clue for Dopamine agonists?
Bromocriptine/cabergoline D2 agonism suppresses prolactin rather than broadly suppressing GH/GI peptide release.
What is the common trap with Octreotide and lanreotide vs Dopamine agonists?
Both can touch pituitary endocrinology, but the hormone being suppressed is different.